AI Article Synopsis
- The study aimed to assess the effectiveness of slow-release 5-fluorouracil implantation in treating patients with unresectable pancreatic cancer.
- A total of 85 patients were divided into a trial group receiving the slow-release treatment and a control group, with results showing a significantly higher response and survival rates in the trial group.
- The study concluded that this treatment method is simple, safe, and effective for managing locally advanced pancreatic cancer.
Article Abstract
Objective: To study the role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer.
Methods: 85 cases of untreated patients with locally advanced pancreatic cancer (LAPC) were randomized into two groups: Trial group: slow-release 5-fluorouracil implantation (50 patients) and control group (35 patients). Observing the objective tumor response, clinical benefit response, toxicity, complications and survival of patients of the two groups.
Results: In the trial group the overall response rate (PR + NC) was 76.0%, and the clinical benefit response rate was 52.0%. No toxicity was observed. Pancreatic fistula occurred in 2 patients. The median survival time of the two groups was 9.0 months and 4.0 months, respectively. The survival rates of 6- and 12-month were 56.8% vs. 31.4% and 22.9% vs. 2.9% in the two groups, respectively (P = 0.012).
Conclusion: Slow-release 5-fluorouracil implantation is a simple, safe and effective method in treatment of LAPC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!